Dr. Bazhenova on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC
May 7th 2018Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).
Read More